157 related articles for article (PubMed ID: 22663961)
1. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.
Angeli F; Reboldi G; Mazzotta G; Poltronieri C; Garofoli M; Ramundo E; Biadetti A; Verdecchia P
Curr Drug Saf; 2012 Feb; 7(1):76-85. PubMed ID: 22663961
[TBL] [Abstract][Full Text] [Related]
2. Aliskiren--an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension.
Allikmets K
Vasc Health Risk Manag; 2007; 3(6):809-15. PubMed ID: 18200801
[TBL] [Abstract][Full Text] [Related]
3. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.
Verdecchia P; Angeli F; Mazzotta G; Gentile G; Reboldi G
Vasc Health Risk Manag; 2008; 4(5):971-81. PubMed ID: 19183745
[TBL] [Abstract][Full Text] [Related]
4. Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports.
Dubrall D; Schmid M; Stingl JC; Sachs B
PLoS One; 2020; 15(3):e0230632. PubMed ID: 32214375
[TBL] [Abstract][Full Text] [Related]
5. Renin inhibitors in diabetes and hypertension: an update.
Sen S; Ufuktepe B; Özünal ZG; Üresin Y
EXCLI J; 2014; 13():1111-9. PubMed ID: 26417326
[TBL] [Abstract][Full Text] [Related]
6. Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus.
Seki Y; Morimoto S; Kimura S; Takano N; Yamashita K; Bokuda K; Sasaki N; Watanabe D; Ichihara A
Kidney Blood Press Res; 2023; 48(1):688-700. PubMed ID: 37866351
[TBL] [Abstract][Full Text] [Related]
7. Renin Inhibition and the Long-Term Renal Function in Patients With Hypertensive Emergency: A Retrospective Cohort Study.
Ueno M; Fujii W; Ono W; Murata H; Fujigaki Y; Shibata S
Am J Hypertens; 2024 May; 37(6):407-414. PubMed ID: 37819695
[TBL] [Abstract][Full Text] [Related]
8. Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients.
Zheng SL; Roddick AJ; Ayis S
Diab Vasc Dis Res; 2017 Sep; 14(5):400-406. PubMed ID: 28844155
[TBL] [Abstract][Full Text] [Related]
9. Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control.
Rashid HU
Integr Blood Press Control; 2010; 3():133-44. PubMed ID: 21949629
[TBL] [Abstract][Full Text] [Related]
10. Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes.
Schmerbach K; Pfab T; Zhao Y; Culman J; Mueller S; Villringer A; Muller DN; Hocher B; Unger T; Thoene-Reineke C
PLoS One; 2010 Nov; 5(11):e15052. PubMed ID: 21124781
[TBL] [Abstract][Full Text] [Related]
11. Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules.
Ramya K; Suresh R; Kumar HY; Kumar BRP; Murthy NBS
Bioorg Med Chem; 2020 May; 28(10):115466. PubMed ID: 32247750
[TBL] [Abstract][Full Text] [Related]
12. Direct renin inhibitors: a new approach to antihypertensive drug treatment.
Ram CV
J Clin Hypertens (Greenwich); 2007 Aug; 9(8):615-21. PubMed ID: 17673883
[TBL] [Abstract][Full Text] [Related]
13. Renin-Angiotensin System Inhibitors Suppress the Growth of Leukemia Cells.
Itoh M; Sasaki S; Tohda S
Anticancer Res; 2024 Mar; 44(3):1183-1192. PubMed ID: 38423665
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren-Loaded Nanoparticles Downregulate (Pro)renin Receptor and ACE Gene Expression in the Heart of Spontaneously Hypertensive Rats: Effect on NADPH Oxidase.
Barta A; Cebova M; Kovac A; Koneracka M; Zavisova V; Pechanova O
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255922
[TBL] [Abstract][Full Text] [Related]
15. Role of aliskiren in blood pressure control and renoprotection.
Trimarchi H
Int J Nephrol Renovasc Dis; 2011; 4():41-8. PubMed ID: 21694948
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren in hypertension: evidence for its potential therapeutic value.
Peter D
Core Evid; 2005; 1(1):13-22. PubMed ID: 22496673
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: A comparative review.
Alshahrani S
Front Pharmacol; 2023; 14():1101068. PubMed ID: 36860293
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of aliskiren: practical implications for clinicians.
Angeli F; Reboldi G; Poltronieri C; Angeli E; De Filippo V; Crocetti A; Bartolini C; D'Ambrosio C; Verdecchia P
Curr Drug Saf; 2014; 9(2):106-17. PubMed ID: 24517108
[TBL] [Abstract][Full Text] [Related]
19. Review of direct renin inhibition by aliskiren.
Friedrich S; Schmieder RE
J Renin Angiotensin Aldosterone Syst; 2013 Sep; 14(3):193-6. PubMed ID: 23873285
[TBL] [Abstract][Full Text] [Related]
20. [Austrian Consensus on High Blood Pressure 2019].
Weber T; Arbeiter K; Ardelt F; Auer J; Aufricht C; Brandt MC; Dichtl W; Ferrari J; Föger B; Henkel M; Hohenstein-Scheibenecker K; Horn S; Kautzky-Willer A; Kepplinger E; Knoflach M; Koppelstätter C; Mache C; Marschang P; Mayer G; Metzler B; Oberbauer R; Obermair F; Obermayer-Pietsch B; Perl S; Pilz S; Prischl FC; Podczeck-Schweighofer A; Rebhandl E; Rohla M; Roller-Wirnsberger R; Saely CH; Siostrzonek P; Slany J; Stoschitzky K; Waldegger S; Wenzel RR; Weiss T; Wirnsberger G; Winhofer-Stöckl Y; Zweiker D; Zweiker R; Watschinger B; ; ; ; ; ; ; ; ; ; ; ; ;
Wien Klin Wochenschr; 2019 Nov; 131(Suppl 6):489-590. PubMed ID: 31792659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
